Since the 1970s, the transplant literature has been soaring with anti rejection medications. In the last decade, we as nephrologists are starting to learn from Rheumatology and Oncology on novel targets to treat GNs and Rejections in grafts. A recent review in CJASN highlights the different categories of agents in immunosuppression that we have to our disposal.
T cell directed therapy that target signal 1 from TCR and antigen presenting cell such as OKT3 and and CNIs
T cell directed therapy that target signal 2 that is costimulatory such as Abatecept and belatacept. In addition, there are newer agents being developed for co situmatory blockade by CD154;CD40 targeting.
B cell directed therapy such as Anti CD20 agents such as rituximab, ocrelizumab and veltuzumab
B cell directed therapy such as Anti CD22 agents such as epratuzumab being tried in SLE
B cell targeting agents for B cell differentiation such as belimumab and atacicept.
Plasma cell targeting agents such as bortezomib( carfilzomib hasn't entered the renal world yet)
Complement inhibitors such as eculizumab
Cytokine targeting agents such as steroids
Specific cytokine agents such as anti IL-2 antagonist( basiliximab) and anti TNF alpha
IL-1 antagonists such as anikinra and canakinumab
IL-6 inhibition by tocilizumab being studied in transplant patients
IL-17 inhibition by secukinumab not currently being utilized in renal patients
mTOR inhibitor such as sirolimus and everolimus
Anti CD52 such as campath and alemtuzumab
Inhibition of DNA synthesis by azathioprine, mycophenolate, and leflunomide
Cytotoxic agents such as cyclophosphamide used for many GNs
Finally, pooled polyclonal abs such as IVIG have been used and polyclonal antithymocyte globulins for induction.
Monday, July 13, 2015
Sunday, July 5, 2015
OncoNephrology CME conference in NY 2015
Tuesday, June 30, 2015
Topic Discussion: What is the incidence of MGRS?
There
is a new entity that is now being defined as MGRS ( when MGUS affects the
kidney). The incidence of MGUS rises with age and there is lifetime 1% risk of
transforming to myeloma or other cancers such as amyloidosis.
What is the incidence of MGRS? So what percentage of MGUS
patients develop renal disease? Turns out, no published work has this answer. An abstract presented at American society of
Hematology (ASH) in 2013 might have the closest answer.
The study looked at a large database of lab values and 15
year follow up analyzed. 425 confirmed
MGUS patients with no progression to Myeloma were evaluated. 297 patients had MGUS and normal renal function
at baseline. Over median of 852 days ,
21/297 developed renal Impairment. 15/21
had monoclonal free light chain production.
Time to renal impairment was shorter with the higher free light chain
ratio at baseline. Patients with involved Free light chain >100mg/dl were at
the highest risk of renal failure. So
based on this one study, there is about 7% risk of MGRS from MGUS. Seems high but we really need to wait
published data on this topic. If it is truly 7%, screening with UA and
protein/crt ratio with a complete metabolic panel might be indicated in
patients with rising FLC ratios.
Labels:
MGRS,
MGUS,
onco nephrology,
paraproteins,
topic discussions
Sunday, June 28, 2015
Saturday, June 27, 2015
ASN and NBPAS
Recent changes to MOC and criticism of ABIM, where does nephrology stand. Bold move by ASN to interview with founder of the new organization National Board of Physicians and Surgeons(NBPAS).
I think starting this discussion now is so critical. Hats off to Tod Ibrahim and ASN to take this initiative as we need to redefine that is reasonably priced and truly looks at clinical work that we do.
http://asn-online.org/media/podcast.aspx?p=kidneynews&e=2015_06_25_Teirstein.mp3
I think starting this discussion now is so critical. Hats off to Tod Ibrahim and ASN to take this initiative as we need to redefine that is reasonably priced and truly looks at clinical work that we do.
http://asn-online.org/media/podcast.aspx?p=kidneynews&e=2015_06_25_Teirstein.mp3
Tuesday, June 23, 2015
IN the NEWS: GN Types and ESRD
How do different GN
types do on ESRD? A recent USRDS analysis looked at this very question.
1. Over
84,000 patients were found to have GN that were on ESRD In the time period reviewed
2. Interestingly
IgA nephropathy had the fewest other comorbidities and the lowest use of
hemodialysis
3. Crude
mortality was also lowest in IgA nephropathy patients
4. Highest
mortality was in Lupus nephritis and diabetic nephropathy patients when
compared to IgAN
5. Patients
with ADPKD had a relatively favorable comorbidity and laboratory profile, comparable
with that in IgAN.
6. Overall,
LN patients did the worst of all GNs.
7. Cardiovascular
disease accounted for the highest proportion of deaths within all GN subtypes,
ranging from 34.2% in vasculitis to 44.6% in FSGS.
8. The
highest proportion of infection-related deaths was observed in LN
9. There
were marked survival discrepancies that persisted even after adjustment for
socio demographic and clinical factors.
10. Some
GN subtypes (e.g., IgAN) conferred a particularly favorable prognosis, superior
to that in ADPKD as stated above but, LN displayed shortened survival, similar
to in patients with ESRD caused by diabetes.
These are some very
important findings of the study. Categorizing GNs as on major cause of ESRD
might be not helping us figure out the long term outcomes. As expected IgA and
ADPKD have better survivals and some of the autoimmune and immunosuppressive prone
GNs had worse outcomes.
Labels:
CKD and ESRD,
glomerular diseases,
In The News
Saturday, June 6, 2015
OncoNephrology Conference 2015
We are conducting a one day symposium on OncoNephrology: Cancer, chemotherapy and the Kidney at Hofstra NSLIJ School of Medicine on Sept 26th, 2015 from 7:30AM to 4PM
The conference will highlight and review the latest happenings in OncoNephrology
Talks and Speakers highlighted;
AKI in Cancer Patients; Joseph Bonventre, Harvard Medical School
Chemotherapy Toxicities: Mark Perazella, Yale University
Targeted Therapy and the Kidney: Kenar Jhaveri, Hofstra University
Hypercalcemia of Malignancy: Naveed Masani, Winthrop University
Anemia, CKD, ESKD and cancer: Steven Fishbane, Hofstra University
Renal Cancer, an update: Thomas Bradley, Hofstra University, NSLIJ Cancer Institute
Paraneoplastic GN; Hitesh H Shah, Hofstra University
TMA: Bradley Dixon, Cincinnati Children Hospital
Post Kidney Transplant Cancers: Vinay Nair, Mt Sinai Medical Center
Paraproteinemias, an update: Gerald Appel, Columbia University Medical Center
Cases with the Onconephropathologist: Glen Markowitz, Columbia Medical Center
Course directors: Kenar Jhaveri, Steven Fishbane and Thomas Bradley( Division of Nephrology and Hematology/Oncology at Hofstra NSLIJ School of Medicine)
Planning committee: Kenar Jhaveri, Steven Fishbane and Thomas Bradley, Hitesh H Shah, Pravin Singhal, Jyotsana Thakkar and Rimda Wanchoo( all from Division of Nephrology, Hofstra NSLIJ School of Medicine)
To Register: go here
Full brochure coming soon.
This conference is endorsed by




The conference will highlight and review the latest happenings in OncoNephrology
Talks and Speakers highlighted;
AKI in Cancer Patients; Joseph Bonventre, Harvard Medical School
Chemotherapy Toxicities: Mark Perazella, Yale University
Targeted Therapy and the Kidney: Kenar Jhaveri, Hofstra University
Hypercalcemia of Malignancy: Naveed Masani, Winthrop University
Anemia, CKD, ESKD and cancer: Steven Fishbane, Hofstra University
Renal Cancer, an update: Thomas Bradley, Hofstra University, NSLIJ Cancer Institute
Paraneoplastic GN; Hitesh H Shah, Hofstra University
TMA: Bradley Dixon, Cincinnati Children Hospital
Post Kidney Transplant Cancers: Vinay Nair, Mt Sinai Medical Center
Paraproteinemias, an update: Gerald Appel, Columbia University Medical Center
Cases with the Onconephropathologist: Glen Markowitz, Columbia Medical Center
Course directors: Kenar Jhaveri, Steven Fishbane and Thomas Bradley( Division of Nephrology and Hematology/Oncology at Hofstra NSLIJ School of Medicine)
Planning committee: Kenar Jhaveri, Steven Fishbane and Thomas Bradley, Hitesh H Shah, Pravin Singhal, Jyotsana Thakkar and Rimda Wanchoo( all from Division of Nephrology, Hofstra NSLIJ School of Medicine)
To Register: go here
Full brochure coming soon.
This conference is endorsed by
Subscribe to:
Posts (Atom)
